A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

NCT04551352 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Melanoma
Uveal Melanoma
Mucosal Melanoma

Interventions

DRUG: RO7293583
DRUG: Tocilizumab
DRUG: Obinutuzumab
DRUG: Adalimumab

Sponsor

Hoffmann-La Roche